How big is the Retinopathy of Prematurity Market | Manufacturers and Suppliers List 2025

How big is the Retinopathy of Prematurity Market?

The market is growing due to factors like the rising incidence of preterm births, the growing use of neonatal intensive care, and improvements in diagnostic imaging and therapeutic equipment.

Key Growth Drivers of the Retinopathy of Prematurity Market

• Increasing incidence of preterm births and low birth weight infants requiring neonatal eye screening
• Rising adoption of retinal imaging devices and wide-field digital imaging systems
• Advances in laser therapy, anti-VEGF injections, and surgical interventions
• Growing awareness of early screening and treatment among healthcare providers
• Integration of telemedicine and AI-enabled diagnostic tools in neonatal care

Retinopathy of Prematurity Market Trends

The Retinopathy of Prematurity Market is expanding with trends such as AI-assisted retinal screening, tele-ophthalmology, and cloud-based imaging solutions. Portable retinal cameras, digital documentation, and automated image analysis are gaining popularity. Partnerships between hospitals and technology providers are improving early diagnosis, treatment accuracy, and patient outcomes. Additionally, the efficiency of clinical workflow is being improved through the integration of decision-support tools and predictive analytics.

Emerging Developments in the Retinopathy of Prematurity Market

Emerging Developments in the Retinopathy of Prematurity Market include AI-enabled disease grading, remote screening platforms, and compact imaging devices suitable for NICUs. Adoption is increasing in developing regions with limited ophthalmology specialists. Additionally, research into new therapeutics, laser-anti-VEGF treatments, and telemedicine-enabled follow-ups is increasing, which improves access and lowers the risk of vision impairment. Innovation in early detection and treatment solutions is also being fueled by partnerships between technology companies and healthcare providers.

List of Leading Companies in the Retinopathy of Prematurity Market

Below is a comprehensive list of the leading market players driving growth in this sector:

1. Novartis AG

This company develops therapies for ROP and other retinal disorders in neonates. Novartis focuses on innovative ophthalmic drugs, clinical research, and improving vision outcomes for premature infants.

2. Regeneron Pharmaceuticals, Inc.

This company provides therapies targeting retinal vascular diseases, including ROP. Regeneron emphasizes clinical efficacy, safety, and advancements in neonatal ophthalmology.

3. Roche Holding AG (Genentech)

This company offers treatments and diagnostics for retinal diseases, including ROP. Roche focuses on precision medicine, innovative ophthalmic therapies, and improving neonatal vision care.

4. Bayer AG

This company develops therapeutic solutions for retinal vascular disorders affecting premature infants. Bayer emphasizes research innovation, clinical trials, and enhanced patient outcomes.

5. Allergan (AbbVie)

This company provides ROP therapies and advanced ophthalmic care solutions. Allergan focuses on drug development, patient safety, and improved neonatal eye health.

6. Santen Pharmaceutical Co., Ltd.

This company develops treatments for retinal disorders including ROP and other pediatric eye diseases. Santen emphasizes research-driven solutions and worldwide ophthalmology initiatives.

7. Apellis Pharmaceuticals, Inc.

This company focuses on complement-inhibition therapies for retinal diseases in neonates. Apellis emphasizes targeted treatment mechanisms, clinical research, and preserving vision in premature infants.

8. Oxurion NV

This company develops therapeutics for neonatal retinal vascular disorders including ROP. Oxurion focuses on innovative drug delivery, clinical development, and improving early-life vision outcomes.

9. Kodiak Sciences, Inc.

This company researches treatments for retinal vascular diseases including ROP. Kodiak Sciences emphasizes vision restoration, clinical trials, and innovative therapies for neonatal care.

10. Genentech (Roche Group)

This company provides biologic therapies and research programs for retinal diseases in premature infants. Genentech focuses on advanced treatments, clinical innovation, and neonatal ophthalmology.

How big is the Retinopathy of Prematurity Market : FAQs